SEC Comment Letter 0000000000-24-001975 to Prelude Therapeutics Inc (PRLD) (CIK 0001678660) (PRLD)
Prelude Therapeutics Inc (PRLD) (CIK 0001678660)
Date: Feb. 21, 2024 · CIK: 0001678660 · Accession: 0000000000-24-001975
AI Filing Summary & Sentiment
File numbers found in text: 333-277123
Letter
United States securities and exchange commission logo February 21, 2024 Krishna Vaddi, Ph.D. Chief Executive Officer Prelude Therapeutics Incorporated 175 Innovation Boulevard Wilmington, Delaware 19805 Re:Prelude Therapeutics Incorporated Registration Statement on Form S-3 Filed February 16, 2024 File No. 333-277123 Dear Krishna Vaddi: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Robert Freedman
Show Raw Text
United States securities and exchange commission logo
February 21, 2024
Krishna Vaddi, Ph.D.
Chief Executive Officer
Prelude Therapeutics Incorporated
175 Innovation Boulevard
Wilmington, Delaware 19805
Re:Prelude Therapeutics Incorporated
Registration Statement on Form S-3
Filed February 16, 2024
File No. 333-277123
Dear Krishna Vaddi:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Robert Freedman